Stocktoria
Neuphoria Therapeutics Inc. NEUP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1999-12-21
Neuphoria Therapeutics Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating margin | -7.2% | — | — |
| Net margin | -2.6% | — | — |
| Return on assets | -1.4% | -56.0% | -74.9% |
| Return on equity | -2.1% | -88.6% | -97.1% |
| Current ratio | 3.56 | 3.45 | 4.87 |
Source: SEC EDGAR filings · CIK 0001191070 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.